IMPROVE-CKD Study: Impact Of A Phosphate Binder On Cardiovascular Disease In Chronic Kidney Disease.
Funder
National Health and Medical Research Council
Funding Amount
$1,596,698.00
Summary
Chronic kidney disease (CKD) is a significant health problem and is associated with an increased risk of cardiovascular (CV) disease. Vascular calcification and arterial stiffness (stiffening of the blood vessels and arteries) are very common in people with CKD, and are linked to increased death from CV events. This study aims to examine the ways in which treatment with a phosphate binder, Lanthanum Carbonate, may reduce vascular calcification and arterial stiffness to decrease CV events.
Calcification of the arteries is a ubiquitous finding in patients with end stage renal failure. It is often mirrored by disturbed bone metabolism. Increasing evidence suggests a close relationship between bone and vascular health. This study aims to determine the role of calciprotein particles as a mediator of calcification in bones and arteries. Translating these findings to renal patients will ultimately contribute to providing a scientific basis for developing treatment for these patients.
Defining The Central Role Of Podocyte Depletion In The Development, Progression And Management Of Glomerular Disease
Funder
National Health and Medical Research Council
Funding Amount
$690,855.00
Summary
Podocytes are key cellular components of the kidney’s filtration barrier. Podocyte depletion (cell loss or injury) is a key event in most forms of kidney disease. We will investigate interactions between podocyte depletion and two major risk factors for kidney disease (diabetes and hypertension), assess whether podocyte depletion influences therapeutic outcomes, and commence efforts to develop podocyte-specific therapies.
Generating Endogenous Antigen Specific T Regulatory Cells To Treat Autoimmune MPO-ANCA GN
Funder
National Health and Medical Research Council
Funding Amount
$885,566.00
Summary
Glomerulonephritis (GN) is an inflammatory disease that affects the filtering organs (glomeruli) of the kidney. The most severe and aggressive form is ANCA-associated GN resulting from loss of tolerance to myeloperoxidase (MPO). Current therapies are toxic. This study will develop new strategies to restore immune tolerance to MPO thus treating patients with this disease. We will use an animal model to provide proof-of-concept that these novel therapies can treat MPO-ANCA associated GN.
Cardiovascular Disease; Priorities And Outcomes For People With Chronic And End Stage Kidney Disease
Funder
National Health and Medical Research Council
Funding Amount
$81,976.00
Summary
This thesis will investigate the patterns, causes and effects of heart disease in chronic kidney disease patients; how heart disease impacts on hospital admission patterns and mortality over time. We will explore the relationship between cognition, cardiovascular and kidney disease; the impact on patient outcomes and quality of life. Finally, we will explore how current research funding reflects disease burden, research output and the stated priorities of patients with chronic kidney disease.
Implementing Innovative Trial Methodologies For Chronic Disease
Funder
National Health and Medical Research Council
Funding Amount
$128,224.00
Summary
Chronic kidney disease and diabetes are associated with increased cardiovascular disease, hospitalisation and mortality. Health can be improved through better delivery of care. I plan to perform a population based study to identify people with kidney disease or diabetes who do are not receiving optimal care as described in current guidelines. From this, I plan to develop a trial to close the gap. I also plan to assess whether data linkage is an accurate method to conduct trial follow-up.
The SHARP-ER Study: Extended Follow-up Of The SHARP Study Cohort
Funder
National Health and Medical Research Council
Funding Amount
$1,106,265.00
Summary
The SHARP study, conducted from 2003 to 2010, recruited over 9,000 participants with kidney disease and showed, for the first time, that cholesterol-lowering was effective in preventing heart and vascular disease in people with advanced kidney disease. This study will extend follow-up to answers critical questions regarding long-term cardiovascular, renal and other health outcomes.
Growing The Evidence Base For Improved Outcomes In Chronic Kidney Disease
Funder
National Health and Medical Research Council
Funding Amount
$697,209.00
Summary
One in eight Australians has kidney disease, and is at increased risk of kidney failure, heart disease and stroke, and premature death. Despite this, very few treatments have been proven to be be effective at improving these outcomes. Professor Perkovic will undertake a suite of high-quality randomised trials and systematic reviews that will reliably identify new treatment approaches that will result in better quality and quantity of life for the millions of Australians affected by kidney diseas ....One in eight Australians has kidney disease, and is at increased risk of kidney failure, heart disease and stroke, and premature death. Despite this, very few treatments have been proven to be be effective at improving these outcomes. Professor Perkovic will undertake a suite of high-quality randomised trials and systematic reviews that will reliably identify new treatment approaches that will result in better quality and quantity of life for the millions of Australians affected by kidney diseaseRead moreRead less
Renal failure is a major cause of morbidity and mortality in persons with diabetes mellitus and accounts for the majority of renal disease worldwide. Renal fibrosis is the end result of progressive kidney disease. The proposed research aims to identify a new strategy by targeting specific channels in kidney cell membranes to arrest the development of enal fibrosis and hence progressive kidney disease caused by diabetes mellitus.